600276 恒瑞医药
2025/09 - 九个月
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额9,110,4307,422,7537,643,6651,265,2654,218,816
投资活动产生之现金流量净额(1,526,267)(1,911,986)1,222,315390,289(546,263)
筹资活动产生之现金流量净额8,091,020(1,550,590)(3,144,426)(318,770)(998,322)
汇率变动对现金及现金等价物的影响(146,578)7,40112,53380,497(16,866)
现金及现金等价物净增加/(减少)15,528,6063,967,5785,734,0871,417,2812,657,365
期初现金及现金等价物余额24,239,10220,271,52414,537,43713,120,15610,462,791
期末现金及现金等价物余额39,767,70824,239,10220,271,52414,537,43713,120,156